The short version
Only one company currently supplies this market — there is no backup if it stumbles.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Curist Hives Relief
Fexofenadine Hydrochloride 180 mg · FEXOFENADINE HYDROCHLORIDE 180 mg/1 · Tablet · Oral · Little Pharma, Inc.
NDC 72559-0028-40 · 60 TABLET in 1 BOTTLE · ANDA · View full market →
Medicare Part D
No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.
How Part D pricing works →NADAC price per unit
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Supply fragility
Not scored — fragility is computed for NADAC-priced NDCs.
90-day shortage risk (model v2)
0.1%chance of a new FDA shortage posting for fexofenadine hydrochloride 180 mg (oral solid) in the next 90 days
sole-source market
For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.
Backtested statistical model over the whole market, not this package alone. Model details →
Regulatory
- Application
- ANDA204507
- TE code
- —
- Approval date
- Sep 16, 2015
- Patents / exclusivity
- None on file
Shortage history
No FDA shortage reports for this drug or its presentations.
Recalls (this NDC)
No enforcement reports list this package NDC.
Manufacturers of Fexofenadine Hydrochloride 180 mg (Tablet)
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Little Pharma, Inc. | FEXOFENADINE HYDROCHLORIDE 180 mg/1 | Jul 15, 2026 | Aug 28, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
Cite this page
DrugDashboards, "Curist Hives Relief — NDC 72559-0028-40," retrieved September 3, 2026, https://drugdashboards.com/drug/72559002840.
Free to cite with attribution — see how the data is put together.